Cited by 1,336Renal cell carcinoma treatmentCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

Open access

The Cancer Genome Atlas Research Network·2016·New England Journal of Medicine

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS: We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2-antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtypes based on molecular and phenotypic features. (Funded by the National Institutes of Health.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1505917

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Self-citation
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Self-citation
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635

Flagged first, then by citations

Show all 42 references

1 of the 42 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Delahunt B, 1997, Mod Pathol, 10, 537
Schmidt LS, 1998, Cancer Res, 58, 1719

Sorted by citations

Items 301–400 of 1,000

Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
Elgendy, M., Fusco, J. P., Segura, V., Lozano, M. D., Minucci, S., Echeveste, J. I., Gúrpide, A., Andueza, M., Melero, I., Sanmamed, M. F., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32256 · Cited by 41
Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase–deficient renal cell carcinoma
Zheng, L., Zhu, Z.-R., Sneh, T., Zhang, W.-T., Wang, Z.-Y., Wu, G., He, W., Qi, H., Wang, H., Wu, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165028 · Cited by 39
Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression
Ruan, P., Todd, J. L., Zhao, H., Liu, Y., Vinisko, R., Söllner, J. F., Schmid, R., Kaner, R. J., Luckhardt, T., Neely, M. L., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02435-0 · Cited by 43
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer
Srinivasan, R., Gurram, S., Singer, E. A., Sidana, A., Harthy, M. A., Ball, M. W., Friend, J. C., Mac, L. M., Purcell, E., Vocke, C. D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2200900 · Cited by 39
Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database
Favazza, L. A., Chitale, D. A., Barod, R., ROGERS, C. G., Sundaram, S. K., Palanisamy, N., Gupta, N., & Williamson, S. R. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.72 · Cited by 39
SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response
McEvoy, C. R. E., Koe, L., Choong, D., Leong, H. S., Xu, H., Karikios, D. J., Plew, J. D., Prall, O. W. J., FELLOWES, A. P., & Fox, S. B. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0053-2 · Cited by 39
MiT family translocation renal cell carcinomas: A 15th anniversary update.
Gandhi, J. S., Malik, F. A., Amin, M. B., Argani, P., & Bahrami, A. (2020) · PubMed · doi:10.14670/hh-18-159 · Cited by 39
Identification of Pan-Cancer Prognostic Biomarkers Through Integration of Multi-Omics Data
Zhao, N., Guo, M., Wang, K., Zhang, C., & Liu, X. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00268 · Cited by 39
Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
Feldman, D. R., Ged, Y. M. A., Lee, C., Knežević, A., Molina, A. M., Chen, Y., Chaim, J. L., Coskey, D. T., Murray, S. J., Tickoo, S. K., et al. (2020) · Cancer · doi:10.1002/cncr.33148 · Cited by 39
Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data
Barthélémy, P., Rioux-Leclercq, N. C., Thibault, C., Saldana, C., Borchiellini, D., Chevreau, C., Desmoulins, I., Gobert, A., Hilgers, W., Khalil, A., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102191 · Cited by 39
Oncometabolites—A Link between Cancer Cells and Tumor Microenvironment
Baryła, M., Semeniuk-Wojtaś, A., Róg, L., Kraj, L., Małyszko, M., & Stec, R. (2022) · Biology · doi:10.3390/biology11020270 · Cited by 40
Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)
Ghatalia, P., & Rathmell, W. K. (2018) · Kidney Cancer · doi:10.3233/kca-170021 · Cited by 38
Machine learning models to predict the progression from early to late stages of papillary renal cell carcinoma
Singh, N., Bapi, R. S., & Vinod, P. K. U. (2018) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2018.06.030 · Cited by 40
High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma
Polifka, I., Agaimy, A., Herrmann, E., Spath, V., Trojan, L., Stöckle, M., Becker, F. O., Ströbel, P., Wülfing, C., Schrader, A. J., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.08.006 · Cited by 38
A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion
Fukuda, H., Kato, I., Furuya, M., Tanaka, R. J., Takagi, T., Kondo, T., & Nagashima, Y. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2509-8 · Cited by 38
Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma
Barth, D. A., Slabý, O., Klec, C., Juráček, J., Drulă, R., Calin, G. A., & Pichler, M. (2019) · Cancers · doi:10.3390/cancers11101580 · Cited by 38
Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering
Arora, A., Olshen, A. B., Seshan, V., & Shen, R. (2020) · Genome Medicine · doi:10.1186/s13073-020-00804-8 · Cited by 38
Hippo Pathway in Regulating Drug Resistance of Glioblastoma
Casati, G., Giunti, L., Iorio, A. L., Marturano, A., Galli, L., & Sardi, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413431 · Cited by 42
Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases
Skenderi, F., Ulamec, M., Vaněček, T., Martínek, P., Alaghehbandan, R., Pané, M., Babankova, I., Pérez‐Montiel, D., Alvarado‐Cabrero, I., Švajdler, M., et al. (2017) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2017.01.005 · Cited by 38
Epigenomic charting and functional annotation of risk loci in renal cell carcinoma
Nassar, A. H., Alaiwi, S. A., Baca, S. C., Adib, E., Corona, R. I., Seo, J.-H., Fonseca, M. A., Spisák, S., Zarif, T. E., Tisza, V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35833-5 · Cited by 37
TCA cycle-derived oncometabolites in cancer and the immune microenvironment
Sarkar, S., Chang, C.-I., Jean, J., & Wu, M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01186-y · Cited by 39
Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis
Hu, S., Yuan, H., Li, Z., Zhang, J., Wu, J., Chen, Y., Shi, Q., Ren, W., Shao, N., & Ying, X. (2017) · Oncotarget · doi:10.18632/oncotarget.17295 · Cited by 37
Personalized Management of Advanced Kidney Cancer
Graham, J., Heng, D. Y. C., Brugarolas, J., & Vaishampayan, U. N. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201215 · Cited by 37
TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma
Tretbar, S., Krausbeck, P., Müller, A., Friedrich, M., Vaxevanis, C., Bukur, J., Jasinski‐Bergner, S., & Seliger, B. (2019) · Oncotarget · doi:10.18632/oncotarget.26682 · Cited by 37
Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
Mollica, V., Nunno, V. D., Gatto, L., Santoni, M., Scarpelli, M., Cimadamore, A., Antonio Lopez-beltran, B., Liang Cheng, C., Battelli, N., Montironi, R., et al. (2019) · Cancers · doi:10.3390/cancers11060830 · Cited by 37
RBM10–TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break‐apart fluorescence in‐situ hybridisation: study of 10 cases and a literature review
Kato, I., Furuya, M., Baba, M., Kameda, Y., Yasuda, M., Nishimoto, K., Oyama, M., Yamasaki, T., Ogawa, O., Niino, H., et al. (2019) · Histopathology · doi:10.1111/his.13866 · Cited by 37
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Pozzessere, C., Bassanelli, M., Ceribelli, A., Rasul, S., Li, S., Prior, J. O., & Cicone, F. (2019) · Current Urology Reports · doi:10.1007/s11934-019-0938-9 · Cited by 37
Metabolic Drivers in Hereditary Cancer Syndromes
Sciacovelli, M., Schmidt, C., Maher, E. R., & Frezza, C. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033612 · Cited by 39
The genomic and epigenomic evolutionary history of papillary renal cell carcinomas
Zhu, B., Poeta, M. L., Costantini, M., Zhang, T., Shi, J., Sentinelli, S., Wei, Z., Pompeo, V., Cardelli, M., Alexandrov, B. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16546-5 · Cited by 38
A Causal Framework for Making Individualized Treatment Decisions in Oncology
Msaouel, P., Lee, J., Karam, J. A., & Thall, P. F. (2022) · Cancers · doi:10.3390/cancers14163923 · Cited by 40
iPSC-Derived Embryoid Bodies as Models of c-Met-Mutated Hereditary Papillary Renal Cell Carcinoma
Hwang, J. W., Desterke, C., Féraud, O., Richard, S., Ferlicot, S., Verkarre, V., Patard, J., Loisel‐Duwattez, J., Foudi, A., Griscelli, F., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194867 · Cited by 36
Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities
Brodziak, A., Sobczuk, P., Bartnik, E., Fiedorowicz, M., Porta, C., Szczylik, C. A., & Czarnecka, A. M. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0233-z · Cited by 36
Anti‐tumor efficacy of human anti‐c‐met CAR‐T cells against papillary renal cell carcinoma in an orthotopic model
Mori, J., Adachi, K., Sakoda, Y., Sasaki, T., Goto, S., Matsumoto, H., Nagashima, Y., Matsuyama, H., & Tamada, K. (2021) · Cancer Science · doi:10.1111/cas.14835 · Cited by 37
Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma
Becerra, M. F., Reznik, E., Redzematovic, A., Tennenbaum, D. M., Kashan, M. Y., Ghanaat, M., Casuscelli, J., Manley, B. J., Jonsson, P., DiNatale, R. G., et al. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.09.016 · Cited by 36
A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Hillen, H., Candi, A., Vanderhoydonck, B., Kowalczyk, W., Sansores-García, L., Kesikiadou, E. C., Huffel, L. V., Spiessens, L., Nijs, M., Soons, E., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0681 · Cited by 35
Amino acids in cancer: Understanding metabolic plasticity and divergence for better therapeutic approaches
Do, L. K., Lee, H. M., Ha, Y., Lee, C., & Kim, J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115529 · Cited by 38
Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach
Alaghehbandan, R., Pérez‐Montiel, D., Luís, A. S., & Hes, O. (2019) · Cancers · doi:10.3390/cancers12010085 · Cited by 35
Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma
Lang, M., Vocke, C. D., Ricketts, C. J., Metwalli, A. R., Ball, M. W., Schmidt, L. S., & Linehan, W. M. (2020) · Urology · doi:10.1016/j.urology.2020.11.025 · Cited by 35
The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
Marchetti, A., Rosellini, M., Mollica, V., Rizzo, A., Tassinari, E., Nuvola, G., Cimadamore, A., Santoni, M., Fiorentino, M., Montironi, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126237 · Cited by 35
Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
Sepe, P., Ottini, A., Pircher, C. C., Franza, A., Claps, M., Guadalupi, V., Verzoni, E., & Procopio, G. (2021) · Cancers · doi:10.3390/cancers13153807 · Cited by 36
Low-grade Oncocytic Fumarate Hydratase-deficient Renal Cell Carcinoma: An Update on Biologic Potential, Morphologic Spectrum, and Differential Diagnosis With Other Low-grade Oncocytic Tumors
Hamza, A., Sirohi, D., Smith, S. C., & Amin, M. B. (2021) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000321 · Cited by 35
Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells
Bielecka, Z. F., Malinowska, A., Brodaczewska, K. K., Klemba, A., Kiéda, C., Krasowski, P., Grzesiuk, E., Piwowarski, J., Czarnecka, A. M., & Szczylik, C. A. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0197-8 · Cited by 36
Tracing Renal Cell Carcinomas back to the Nephron
Lindgren, D., Sjölund, J., & Axelson, H. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.003 · Cited by 40
Crosstalk of organelles in Parkinson’s disease – MiT family transcription factors as central players in signaling pathways connecting mitochondria and lysosomes
Lang, M., Pramstaller, P. P., & Pichler, I. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00555-7 · Cited by 35
The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates
Goswami, P., Singh, G., Patel, T. P., & Dave, R. M. (2024) · Cureus · doi:10.7759/cureus.58470 · Cited by 34
Evolving roles of MET as a therapeutic target in NSCLC and beyond
Lee, J. B., Shim, J. S. G., & Cho, B. C. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01051-9 · Cited by 34
Identification by FFPE RNA‐Seq of a new recurrent inversion leading to RBM10‐TFE3 fusion in renal cell carcinoma with subtle TFE3 break‐apart FISH pattern
Just, P., Letourneur, F., Pouliquen, C., Dome, F., Audebourg, A., Biquet, P., Vidaud, M., Terris, B., Sibony, M., & Pasmant, É. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22356 · Cited by 34
Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation
Zhao, H., Nolley, R., Chan, A., Rankin, E. B., & Peehl, D. M. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1219816 · Cited by 34
Disruption of CUL3-mediated ubiquitination causes proximal tubule injury and kidney fibrosis
Saritas, T., Cuevas, C. A., Ferdaus, M. Z., Kuppe, C., Kramann, R., Moeller, M. J., Floege, J., Singer, J. D., & McCormick, J. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-40795-0 · Cited by 35
Cluster analysis on high dimensional RNA-seq data with applications to cancer research - An evaluation study
Vidman, L., Källberg, D., & Rydén, P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219102 · Cited by 34
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia
Isobe, T., Takagi, M., Sato‐Otsubo, A., Nishimura, A., Nagae, G., Yamagishi, C., Tamura, M., Tanaka, Y., Asada, S., Takeda, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32266-4 · Cited by 36
Cancer subtyping with heterogeneous multi-omics data via hierarchical multi-kernel learning
Wei, Y., Li, L., Zhao, X., Yang, H., Sa, J., Cao, H., & Cui, Y. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac488 · Cited by 33
von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology
Shirole, N. H., & Kaelin, W. G. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.04.011 · Cited by 34
Comprehensive Analyses Revealed Eight Immune Related Signatures Correlated With Aberrant Methylations as Prognosis and Diagnosis Biomarkers for Kidney Renal Papillary Cell Carcinoma
Luo, Y., Chen, D., & Xing, X. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.06.011 · Cited by 33
Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer
Perelli, L., Carbone, F., Zhang, L., Huang, J. K.-L., Le, C. N., Khan, H., Citron, F., Poggetto, E. D., Gutschner, T., Tomihara, H., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00584-1 · Cited by 33
A genetic basis for sex differences in Xp11 translocation renal cell carcinoma
Achom, M., Sadagopan, A., Bao, C., McBride, F., Li, J., Konda, P., Tourdot, R. W., Xu, Q., Nakhoul, M., Gallant, D. S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.038 · Cited by 35
Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma
Alaghehbandan, R., Stehlík, J., Trpkov, K., Magi‐Galluzzi, C., Condom, E., Pané, M., Berney, D. M., Sibony, M., Suster, S. M., Agaimy, A., et al. (2017) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2017.04.007 · Cited by 33
The effect of the papillary renal cell carcinoma subtype on oncological outcomes
Pan, H., Ye, L., Zhu, Q., Yang, Z., & Hu, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-78174-9 · Cited by 33
The Morphological Spectrum of Papillary Renal Cell Carcinoma and Prevalence of Provisional/Emerging Renal Tumor Entities with Papillary Growth
Lobo, J., Ohashi, R., Helmchen, B., Rupp, N. J., Rüschoff, J. H., & Moch, H. (2021) · Biomedicines · doi:10.3390/biomedicines9101418 · Cited by 33
A review of neoplasms with MITF/MiT family translocations.
Wei, S., Testa, J. R., & Argani, P. (2022) · PubMed · doi:10.14670/hh-18-426 · Cited by 33
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
Büttner, F., Winter, S., Stühler, V., Rausch, S., Hennenlotter, J., Fuessel, S., Zastrow, S., Meinhardt, M., Toma, M. I., Jerónimo, C., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01105-y · Cited by 33
MET gene amplification is a mechanism of resistance to entrectinib in ROS1 + NSCLC
Tyler, L. C., Le, A. T., Chen, N., Nijmeh, H., Bao, L., Wilson, T. R., Chen, D., Simmons, B., Turner, K. M., Perusse, D., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14656 · Cited by 32
A Pilot Clinical Study in Characterization of Malignant Renal-cell Carcinoma Subtype with Contrast-enhanced Ultrasound
Kasoji, S. K., Chang, E., Mullin, L. B., Chong, W. K., Rathmell, W. K., & Dayton, P. A. (2016) · Ultrasonic Imaging · doi:10.1177/0161734616666383 · Cited by 32
Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis
He, Z., Sun, M., Ke, Y., Lin, R., Xiao, Y., Zhou, S., Zhao, H., Wang, Y., Zhou, F., & Zhou, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.15842 · Cited by 32
Reactivity of CK 7 across the spectrum of renal cell carcinomas with clear cells
Gonzalez, M. L., Alaghehbandan, R., Pivovarčíková, K., Michalová, K., Rogala, J., Martínek, P., Pané, M., Condom, E., Compérat, É., Ulamec, M., et al. (2018) · Histopathology · doi:10.1111/his.13791 · Cited by 32
The metabolic landscape of urological cancers: New therapeutic perspectives
Miranda‐Gonçalves, V., Lameirinhas, A., Henrique, R., Baltazar, F., & Jerónimo, C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.034 · Cited by 33
Role of the KEAP1-NRF2 Axis in Renal Cell Carcinoma
Clerici, S., & Boletta, A. (2020) · Cancers · doi:10.3390/cancers12113458 · Cited by 36
Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities
Zarrabi, K. K., Walzer, E., & Zibelman, M. R. (2021) · Cancers · doi:10.3390/cancers13153652 · Cited by 32
Recent advances in understanding DNA methylation of prostate cancer
Shin, H. J., Hua, J. T., & Li, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1182727 · Cited by 32
Histone methyltransferase Setd2 is critical for the proliferation and differentiation of myoblasts
Yi, X., Tao, Y., Lin, X., Dai, Y., Yang, T., Yue, X., Jiang, X., Li, X., Jiang, D., Andrade, K. C., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.01.012 · Cited by 35
Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing
Wang, J., Xi, Z., Xi, J., Zhang, H., Li, J., Xia, Y., & Yi, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0661-5 · Cited by 33
Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities
Sirohi, D., Smith, S. C., Agarwal, N., & Maughan, B. L. (2018) · Research and Reports in Urology · doi:10.2147/rru.s154932 · Cited by 32
p32 regulates glycometabolism and TCA cycle to inhibit ccRCC progression via copper-induced DLAT lipoylation oligomerization
Tian, S., Wang, R., Wang, Y., Chen, R., Lin, T., Xiao, X., Liu, X., Ideozu, J. E., Geng, H., Wang, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.84399 · Cited by 31
RETRACTED ARTICLE: Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma
Wu, S., Wang, B., Li, H., Wang, H., Du, S., Huang, X., Fan, Y., Gao, Y., Gu, L., Huang, Q., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03013-4 · Cited by 32
Retracted
Characterization of cytokinome landscape for clinical responses in human cancers
Wong, H. S.-C., Chang, C., Liu, X., Huang, W., & Chang, W. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214789 · Cited by 31
Aligner optimization increases accuracy and decreases compute times in multi-species sequence data
Robinson, K. M., Hawkins, A. S., Santana-Cruz, I., Adkins, R. S., Shetty, A. C., Nagaraj, S., Sadzewicz, L., Tallon, L. J., Rasko, D. A., Fraser, C. M., et al. (2017) · Microbial Genomics · doi:10.1099/mgen.0.000122 · Cited by 33
Genomic features of renal cell carcinoma with venous tumor thrombus
Warsow, G., Hübschmann, D., Kleinheinz, K., Nientiedt, C., Heller, M., Coile, L. V., Tolstov, Y. L., Trennheuser, L., Wieczorek, K. S., Pecqueux, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25544-z · Cited by 31
Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2
Wong, E. C. L., Lena, R. D., Breau, R. H., Pouliot, F., Finelli, A., Lavallée, L. T., So, A., Tanguay, S., Fairey, A., Rendon, R., et al. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.05.009 · Cited by 31
NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma
Paintal, A., Tjota, M. Y., Wang, P., Fitzpatrick, C. A., Wanjari, P., Stadler, W. M., Gallan, A. J., Segal, J. P., & Antic, T. (2022) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001846 · Cited by 31
The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma
Srivastava, A., Doppalapudi, S. K., Patel, H. V., Srinivasan, R., & Singer, E. A. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000831 · Cited by 31
Regulation and Dysregulation of Chromosome Structure in Cancer
Hnisz, D., Schuijers, J., Li, C. H., & Young, R. A. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050134 · Cited by 31
Signaling Complexity Measured by Shannon Entropy and Its Application in Personalized Medicine
Conforte, A. J., Tuszyński, J. A., da Silva, F. A. B., & Carels, N. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00930 · Cited by 31
Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma
van der Mijn, J. C., Fu, L., Khani, F., Zhang, T., Molina, A. M., Barbieri, C. E., Chen, Q., Gross, S. S., Gudas, L. J., & Nanus, D. M. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.10.015 · Cited by 31
Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma
Singh, N., & Vinod, P. K. U. (2020) · Molecular Genetics and Genomics · doi:10.1007/s00438-020-01664-y · Cited by 31
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment
del Alba, A. G., Arranz, J. Á., Puente, J., Méndez-Vidal, M. J., Gallardo, E., Grande, E., Pérez‐Valderrama, B., González‐Billalabeitia, E., Lázaro-Quintela, M., Pinto, Á., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.010 · Cited by 30
Profiling of the metabolic transcriptome via single molecule molecular inversion probes
de Bitter, T. J. J., van de Water, C., van den Heuvel, C. N. A. M., Zeelen, C., Eijkelenboom, A., Tops, B. B. J., Oosterwijk, E., Kolev, D., Mulders, P., ter Laan, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11035-0 · Cited by 30
Comprehensive Analysis of BAP1 Somatic Mutation in Clear Cell Renal Cell Carcinoma to Explore Potential Mechanisms in Silico
Jin, S., Wu, J., Zhu, Y., Gu, W., Wan, F., Xiao, W., Dai, B., Zhang, H., Shi, G., Shen, Y., et al. (2018) · Journal of Cancer · doi:10.7150/jca.27281 · Cited by 30
Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion.
Lo, U., Bao, J., Cen, J., Yeh, H., Luo, J., Tan, W., & Hsieh, J. (2019) · Europe PMC (PubMed Central) · Cited by 30
The lncRNA MEG3 mediates renal cell cancer progression by regulating ST3Gal1 transcription and EGFR sialylation
Gong, A., Zhao, X., Pan, Y., Qi, Y., Li, S., Huang, Y., Guo, Y., Qi, X., Zheng, W., & Jia, L. (2020) · Journal of Cell Science · doi:10.1242/jcs.244020 · Cited by 30
Prognostic risk signature based on the expression of three m6A RNA methylation regulatory genes in kidney renal papillary cell carcinoma
Sun, Z., Jing, C., Xiao, C., Li, T., & Wang, Y. (2020) · Aging · doi:10.18632/aging.104053 · Cited by 30
Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma
Xia, R., Xiao, J., Zhang, Y., Teng, H., Cheng, F., Chen, H., Zhang, K., & Sun, Z. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920977117 · Cited by 30
Gene of the month: FH
Zyla, R. E., & Hodgson, A. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207830 · Cited by 31
The multi-omic landscape of transcription factor inactivation in cancer
Teschendorff, A. E., Zheng, S., Feber, A., Yang, Z., Beck, S., & Widschwendter, M. (2016) · Genome Medicine · doi:10.1186/s13073-016-0342-8 · Cited by 30
Single-Cell mRNA Sequencing in Cancer Research: Integrating the Genomic Fingerprint
Müller, S., & Diaz, A. A. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00073 · Cited by 30
Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases
Pan, X., Zhang, M., Yao, J., Zeng, H., Nie, L., Gong, J., Chen, X., Xu, M., Zhou, Q., & Chen, N. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205924 · Cited by 29
Investigational MET inhibitors to treat Renal cell carcinoma
Nandagopal, L., Sonpavde, G., & Agarwal, N. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1673366 · Cited by 29
Unsupervised Resolution of Histomorphologic Heterogeneity in Renal Cell Carcinoma Using a Brain Tumor–Educated Neural Network
Faust, K., Roohi, A., Leon, A. J., Leroux, E., Dent, A., Evans, A. J., Pugh, T. J., Kalimuthu, S. N., Djuric, U., & Diamandis, P. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.20.00035 · Cited by 29
HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas
Sun, M., Tong, P., Kong, W., Dong, B., Huang, Y., Park, I. Y., Zhou, L., Liu, X.-D., Ding, Z., Zhang, X., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0986 · Cited by 29
Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program
Bodnar, L., Kopczyńska, A., Żołnierek, J., Wieczorek-Rutkowska, M., Chrom, P., & Tomczak, P. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.02.002 · Cited by 29
Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : prise en charge du cancer du rein
Bensalah, K., Albiges, L. K., Bernhard, J., Bigot, P., Bodin, T., Boissier, R., Corréas, J.-M., Gimel, P., Hetet, J. F., Long, J., et al. (2018) · The French Journal of Urology · doi:10.1016/j.purol.2019.01.004 · Cited by 29

Authors: The Cancer Genome Atlas Research Network
Affiliations: National Institutes of Health (US)
Corresponding author: The Cancer Genome Atlas Research Network
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-01-14
Volume: 374
Issue: 2
Pages: 135-145
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1505917
PMC: PMC4775252
OpenAlex: W2111867681
Cited by: 1,336
References: 42
Citations by year: 2026: 60 · 2025: 100 · 2024: 95 · 2023: 130 · 2022: 135 · 2021: 159 · 2020: 153 · 2019: 151 · 2018: 128 · 2017: 126 · 2016: 96
FWCI: 92.55
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institutes of Health (UL1TR000005)
National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
National Cancer Institute (K24CA172355, U24CA143882, U24CA143843, U24CA143840, U24CA143858, U24CA144025, U24CA143866, U24CA199461, U24CA143883, U24CA143845, U24CA180951, U24CA143867, R01CA169172, U24CA143848, U24CA143799, U24CA143835, P30CA008748, P30CA015083, P30CA016672, P30CA016056, P30CA016086)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: papillary renal cell carcinoma, type 2 papillary renal cell carcinoma, MET alterations, SETD2 mutation, TFE3 fusion, Nrf2/ARE pathway, CpG island methylator phenotype, tumor subtypes, prognosis, molecular heterogeneity
MeSH terms: Carcinoma, Papillary, Humans, Kidney Neoplasms, Mutation, Phenotype, RNA, Messenger, RNA, Neoplasm, Signal Transduction, Sequence Analysis, RNA, CpG Islands, DNA Methylation, Proto-Oncogene Proteins c-met, MicroRNAs, NF-E2-Related Factor 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks